Treating cancer with phosphatidylinositol-3-kinase inhibitors: increasing efficacy and overcoming resistance.

Paddock, Marcia N; Field, Seth J; Cantley, Lewis C

Paddock, Marcia N; Field, Seth J; Cantley, Lewis C.

Afiliación

Paddock MN; Meyer Cancer Center Weill Cornell Medicine, New York, NY 10021; Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine, New York, NY 10021.
Field SJ; Department of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, CA 92093. Electronic address: sjfield@ucsd.edu.
Cantley LC; Meyer Cancer Center Weill Cornell Medicine, New York, NY 10021. Electronic address: lcantley@med.cornell.edu.

J Lipid Res ; 60(4): 747-752, 2019 04.

Article en En | MEDLINE | ID: mdl-30718284

Asunto(s)

Antineoplásicos/farmacología; Resistencia a Antineoplásicos/efectos de los fármacos; Neoplasias/tratamiento farmacológico; Fosfatidilinositol 3-Quinasas/metabolismo; Inhibidores de Proteínas Quinasas/farmacología; Animales; Humanos; Neoplasias/metabolismo; Neoplasias/patología

Palabras clave

insulin resistance; insulin signaling; lipid kinases; phosphoinositide; phosphoinositides; receptor tyrosine kinases; signal transduction; targeted therapies

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia a Antineoplásicos / Fosfatidilinositol 3-Quinasas / Inhibidores de Proteínas Quinasas / Neoplasias / Antineoplásicos Límite: Animals / Humans Idioma: En Revista: J Lipid Res Año: 2019 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google